1DJPS College of Pharmacy, Pathri, Dist. Parbhani
2Vasant Pharmacy College, Kaij, Maharashtra
3Gurukrupa Institute of Pharmacy (Degree), Near Chatrapatthi Sugar Factory, NH- 222 Gadi Road, Majalgaon - 431131, Maharashtra
*Corresponding Author E-mail: karwapawan99@gmail.com
Online published on 29 January, 2021.
As we all know the current rapid of the covid-19 in the most of the world has become a pandemic situation. Many research studies have been by various countries to develop a vaccines against the coronavirus SARS-Co V-2. Currently about six vaccine candidates have passed early testing and have entered the clinical trials across the globe, along with more than80 other candidates reported to be in preclinical stages. This state that many different approaches are being moved forward at the same time. However, the destination is not yet completed and so no vaccines are currently licensed for any of the other corona viruses affecting humans. If we go in the past few decades, various vaccines were given to geriatrics as well as paediatrics. So if we look the same in other countries the use of the vaccines is very less or instead some countries have no authentic grant to sell or use the vaccines. Here in this present study we are trying to propose that by the early use of the vaccines also reduced the number of reported COVID-19 cases in a country. So is the combination of these vaccines a reason for the reduced morbidity and mortality and can it be a boon to fight against the disaster of COVID-19 in future.
COVID-19, Vaccines, Morbility, Mortality, Preclinical and clinical testing